Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranibizumab and laser for macular edema due to retinal vein occlusion
NCT01003106Phase 2Completed
- Sponsor
- Peter A Campochiaro
- Start
- Nov 2009
- Primary completion
- Apr 2015
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of ranibizumab in retinal vein occlusion (RVO) (8 arms), sponsored by Peter A Campochiaro. Primary endpoint: Incidence and Severity of Ocular and Non-ocular Adverse Events at 36 months. Started Nov 2009; status: completed.
02
Drugs
ranibizumab
03
Conditions
retinal vein occlusion (RVO)
Beyond the preview
Go deeper on NCT01003106.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01003106.